Want to see HK:3692 full AI Analyst Report?
Hansoh Pharmaceutical Group Company Limited (3692) Ratios
Hansoh Pharmaceutical Group Company Limited Ratios
HK:3692's free cash flow for Q2 2026 was $2.28B. For the 2026 fiscal year, HK:3692's free cash flow was decreased by $-250.79M and operating cash flow was $2.53B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 8.09 | 10.18 | 4.21 | 9.86 | 7.67 |
| Quick Ratio | 7.95 | 9.94 | 4.12 | 9.69 | 7.53 |
| Cash Ratio | 0.78 | 8.39 | 3.27 | 6.72 | 4.86 |
| Solvency Ratio | 1.31 | 1.59 | 0.50 | 0.40 | 0.42 |
| Operating Cash Flow Ratio | 1.53 | 1.43 | 0.45 | 1.05 | 0.85 |
| Short-Term Operating Cash Flow Coverage | 166.37 | 94.49 | 0.74 | 0.00 | 0.00 |
| Net Current Asset Value | $ 31.03B | $ 24.46B | $ 21.64B | $ 18.48B | $ 16.05B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.13 | 0.15 | 0.14 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.17 | 0.19 | 0.19 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.14 | 0.16 | 0.16 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.16 | 0.16 |
| Financial Leverage Ratio | 1.13 | 1.10 | 1.28 | 1.32 | 1.36 |
| Debt Service Coverage Ratio | 109.91 | 74.94 | 0.87 | 44.15 | 47.27 |
| Interest Coverage Ratio | 1712.71 | 602.65 | 42.58 | 45.94 | 54.84 |
| Debt to Market Cap | 0.00 | 0.00 | 0.05 | 0.06 | 0.04 |
| Interest Debt Per Share | 0.02 | 0.02 | 0.70 | 0.75 | 0.66 |
| Net Debt to EBITDA | -0.57 | -5.26 | -4.32 | -4.52 | -3.53 |
| Profitability Margins | |||||
| Gross Profit Margin | 89.89% | 90.98% | 89.80% | 90.73% | 91.24% |
| EBIT Margin | 35.94% | 31.83% | 37.93% | 27.79% | 28.39% |
| EBITDA Margin | 38.56% | 34.89% | 41.56% | 31.25% | 31.04% |
| Operating Profit Margin | 36.04% | 32.88% | 28.10% | 28.47% | 29.15% |
| Pretax Profit Margin | 43.59% | 41.48% | 37.27% | 31.43% | 33.22% |
| Net Profit Margin | 36.97% | 35.66% | 32.44% | 27.54% | 27.31% |
| Continuous Operations Profit Margin | 36.97% | 35.66% | 32.44% | 27.54% | 27.31% |
| Net Income Per EBT | 84.81% | 85.97% | 87.03% | 87.63% | 82.21% |
| EBT Per EBIT | 120.96% | 126.15% | 132.64% | 110.38% | 113.93% |
| Return on Assets (ROA) | 13.92% | 13.81% | 9.92% | 8.61% | 9.99% |
| Return on Equity (ROE) | 15.70% | 15.24% | 12.71% | 11.41% | 13.54% |
| Return on Capital Employed (ROCE) | 15.25% | 13.92% | 10.85% | 9.76% | 12.00% |
| Return on Invested Capital (ROIC) | 12.91% | 11.94% | 8.13% | 8.54% | 9.86% |
| Return on Tangible Assets | 14.05% | 13.92% | 9.97% | 8.62% | 9.99% |
| Earnings Yield | 2.87% | 4.54% | 3.66% | 3.33% | 2.96% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.91 | 3.84 | 3.13 | 2.62 | 2.70 |
| Payables Turnover | 4.54 | 5.07 | 6.29 | 3.91 | 3.50 |
| Inventory Turnover | 2.49 | 1.70 | 1.79 | 1.94 | 2.12 |
| Fixed Asset Turnover | 4.68 | 3.78 | 3.08 | 2.69 | 2.78 |
| Asset Turnover | 0.38 | 0.39 | 0.31 | 0.31 | 0.37 |
| Working Capital Turnover Ratio | 0.54 | 0.52 | 0.45 | 0.43 | 0.57 |
| Cash Conversion Cycle | 140.37 | 238.14 | 262.49 | 233.83 | 202.90 |
| Days of Sales Outstanding | 74.36 | 95.05 | 116.61 | 139.21 | 135.05 |
| Days of Inventory Outstanding | 146.36 | 215.03 | 203.87 | 187.87 | 171.99 |
| Days of Payables Outstanding | 80.35 | 71.93 | 57.98 | 93.24 | 104.14 |
| Operating Cycle | 220.72 | 310.08 | 320.48 | 327.08 | 307.04 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.13 | 0.65 | 0.50 | 0.46 | 0.44 |
| Free Cash Flow Per Share | 1.04 | 0.61 | 0.46 | 0.42 | 0.36 |
| Dividend Paid and CapEx Coverage Ratio | 2.69 | 1.86 | 3.58 | 2.78 | 3.06 |
| Capital Expenditure Coverage Ratio | 13.77 | 17.40 | 14.19 | 10.05 | 5.60 |
| Operating Cash Flow Coverage Ratio | 64.09 | 32.76 | 0.72 | 0.63 | 0.67 |
| Operating Cash Flow to Sales Ratio | 0.45 | 0.32 | 0.31 | 0.29 | 0.26 |
| Free Cash Flow Yield | 3.22% | 3.78% | 3.23% | 3.18% | 2.31% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 34.85 | 22.01 | 27.33 | 30.00 | 33.77 |
| Price-to-Sales (P/S) Ratio | 12.90 | 7.85 | 8.86 | 8.26 | 9.22 |
| Price-to-Book (P/B) Ratio | 5.48 | 3.36 | 3.47 | 3.42 | 4.57 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 31.01 | 26.44 | 30.92 | 31.40 | 43.28 |
| Price-to-Operating Cash Flow Ratio | 28.76 | 24.92 | 28.74 | 28.28 | 35.55 |
| Price-to-Earnings Growth (PEG) Ratio | 1.36 | 0.46 | 2.00 | -6.90 | 7.43 |
| Enterprise Value Multiple | 32.88 | 17.24 | 17.01 | 21.93 | 26.18 |
| Enterprise Value | 190.49B | 73.74B | 71.43B | 64.28B | 80.75B |
| EV to EBITDA | 32.88 | 17.24 | 17.01 | 21.93 | 26.18 |
| EV to Sales | 12.68 | 6.01 | 7.07 | 6.85 | 8.13 |
| EV to Free Cash Flow | 30.48 | 20.26 | 24.66 | 26.04 | 38.14 |
| EV to Operating Cash Flow | 28.27 | 19.09 | 22.92 | 23.45 | 31.33 |
| Tangible Book Value Per Share | 5.86 | 4.79 | 4.08 | 3.82 | 3.38 |
| Shareholders’ Equity Per Share | 5.92 | 4.84 | 4.11 | 3.83 | 3.38 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.15 | 0.14 | 0.13 | 0.12 | 0.18 |
| Revenue Per Share | 2.51 | 2.07 | 1.61 | 1.59 | 1.68 |
| Net Income Per Share | 0.93 | 0.74 | 0.52 | 0.44 | 0.46 |
| Tax Burden | 0.85 | 0.86 | 0.87 | 0.88 | 0.82 |
| Interest Burden | 1.21 | 1.30 | 0.98 | 1.13 | 1.17 |
| Research & Development to Revenue | 0.22 | 0.22 | 0.21 | 0.18 | 0.18 |
| SG&A to Revenue | 0.32 | 0.37 | 0.07 | 0.06 | 0.09 |
| Stock-Based Compensation to Revenue | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 |
| Income Quality | 1.03 | 0.88 | 0.95 | 1.06 | 0.95 |
Currency in CNY
